Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders

Blood

Volumn 110, Issue 9, 2007, Pages 3360-3364

  Gery, Sigal ^a,c   Gueller, Saskia ^a   Chumakova, Katya ^a   Kawamata, Norihiko ^a   Liu, Liqin ^b   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AMGEN INC   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN LNK; STAT3 PROTEIN; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA VIRUS; MOLECULAR BIOLOGY; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; VIRUS ONCOGENE; WILD TYPE;

EID: 36148995898     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-05-089326     Document Type: Article

References (23)

1. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452-2466.
2. Levine RL, Gilliland DG. JAK-2 mutations and their relevance to myeloproliferative disease. Curr Opin Hematol. 2007;14:43-47.
3. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006l;3:e270.
4. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472-3476.
5. Takaki S, Sauer K, Iritani BM, et al. Control of B cell production by the adaptor protein lnk: definition of a conserved family of signal-modulating proteins. Immunity. 2000;13:599-609.
6. Takaki S, Morita H, Tezuka Y, Takatsu K. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein, Lnk. J Exp Med. 2002;195:151-160. Erratum in: J Exp Med. 2002;195:1229.
7. Velazquez L, Cheng AM, Fleming HE, et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med. 2002;195:1599-1611.
8. Nobuhisa I, Takizawa M, Takaki S, et al. Regulation of hematopoietic development in the aortagonad-mesonephros region mediated by Lnk adaptor protein. Mol Cell Biol. 2003;23:8486-8494.
9. Takaki S, Tezuka Y, Sauer K, et al. Impaired lymphopoiesis and altered B cell subpopulations in mice overexpressing Lnk adaptor protein. J Immunol. 2003;170:703-710.
10. Ema H, Sudo K, Seita J, et al. Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnk-deficient mice. Dev Cell. 2005;8:907-914.
11. Tong W, Lodish HF. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med. 2004;200:569-580.
12. Buza-Vidas N, Antonchuk J, Qian H, et al. Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK. Genes Dev. 2006;20:2018-2023.
13. Huang X, Li Y, Tanaka K, Moore KG, Hayashi JI. Cloning and characterization of Lnk, a signal transduction protein that links T-cell receptor activation signal to phospholipase C gamma 1, Grb2, and phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A. 1995;92:11618-11622.
14. Takaki S, Watts JD, Forbush KA, et al. Characterization of Lnk: an adaptor protein expressed in lymphocytes. J Biol Chem. 1997;272:14562-14570.
15. Li Y, He X, Schembri-King J, Jakes S, Hayashi J. Cloning and characterization of human Lnk, an adaptor protein with pleckstrin homology and Src homology 2 domains that can inhibit T cell activation. J Immunol. 2000;164:5199-5206.
16. Tong W, Zhang J, Lodish HF. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood. 2005;105:4604-4612.
17. Millot GA, Vainchenker W, Dumenil D, Svinarchuk F. Distinct effects of thrombopoietin depending on a threshold level of activated Mpl in BaF-3 cells. J Cell Sci. 2002;115:2329-2337.
18. Guerriero R, Parolini I, Testa U, et al. Inhibition of TPO-induced MEK or mTOR activity induces opposite effects on the ploidy of human differentiating megakaryocytes. J Cell Sci. 2006;119:744-752.
19. Geddis AE, Fox NE, Kaushansky K. Phosphatidylinositol 3-kinase is necessary but not sufficient for thrombopoietin-induced proliferation in engineered Mpl-bearing cell lines as well as in primary megakaryocytic progenitors. J Biol Chem. 2001;276:34473-34479.
20. Herrington J, Diakonova M, Rui L, Gunter DR, and Carter-Su C. SH2-B is required for growth hormone-induced actin reorganization. J Biol Chem. 2000;275:13126-13133.
21. Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006;107:1864-1871.
22. Hookham MB, Elliott J, Suessmuth Y, et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood. 2007;109:4924-4929.
23. Sharma SV, Gajowniczek P, Way IP, et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell. 2006;10:425-435.